para-Aminoblebbistatin is a water-soluble, non-fluorescent, photostable myosin II inhibitor, developed from blebbistatin.[1] Among the several blebbistatin derivatives it is one of the most promising for research applications.[2][3] Furthermore, it has a favourable overall profile considering inhibitory properties and ADME calculations.[4]
Names | |
---|---|
IUPAC name
(3aS)-3a-Hydroxy-6-methyl-1-(4-aminophenyl)-2,3-dihydropyrrolo[2,3-b]quinolin-4-one
| |
Other names
| |
Identifiers | |
3D model (JSmol)
|
|
ChEMBL | |
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C18H17N3O2 | |
Molar mass | 307.353 g·mol−1 |
Appearance | Yellow solid |
~ 400 μM | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Myosin specificity
editSpecies | Myosin type | IC50 |
---|---|---|
Rabbit | Skeletal muscle myosin S1 | 1.3 μM,[1] 9.22 μM,[4] 0.98 μM[5] |
Dictyostelium discoideum | Myosin II motor domain | 6.6 μM,[1] 8.5 μM[5] |
Human | slow-twitch skeletal muscle fibre (force) | 10 μM[6] |
Pig (left ventricle) | cardiac myosin | 5.3 μM[5] |
Chicken (gizzard) | smooth muscle myosin S1 | 13 μM[5] |
Human (expressed in Sf9 cells) | non-muscle myosin 2A / B / C motor domains | 9 / 20 / 7.2 μM[5] |
Drosophila melanogaster | bodywall muscle fiber | 8.5 μM[5] |
References
edit- ^ a b c Várkuti BH, Képiró M, Horváth IÁ, Végner L, Ráti S, Zsigmond Á, et al. (May 2016). "A highly soluble, non-phototoxic, non-fluorescent blebbistatin derivative". Scientific Reports. 6: 26141. Bibcode:2016NatSR...626141V. doi:10.1038/srep26141. PMC 4886532. PMID 27241904.
- ^ Roman BI, Verhasselt S, Stevens CV (November 2018). "Medicinal Chemistry and Use of Myosin II Inhibitor ( S)-Blebbistatin and Its Derivatives". Journal of Medicinal Chemistry. 61 (21): 9410–9428. doi:10.1021/acs.jmedchem.8b00503. PMID 29878759.
- ^ Rauscher AÁ, Gyimesi M, Kovács M, Málnási-Csizmadia A (September 2018). "Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential". Trends in Biochemical Sciences. 43 (9): 700–713. doi:10.1016/j.tibs.2018.06.006. PMID 30057142.
- ^ a b Roman BI, Guedes RC, Stevens CV, García-Sosa AT (2018). "Recovering Actives in Multi-Antitarget and Target Design of Analogs of the Myosin II Inhibitor Blebbistatin". Frontiers in Chemistry. 6: 179. Bibcode:2018FrCh....6..179R. doi:10.3389/fchem.2018.00179. PMC 5976736. PMID 29881723.
- ^ a b c d e f in press: Gyimesi M, et al. (2020). "Improved inhibitory and ADMET properties of blebbistatin derivatives indicate that blebbistatin scaffold is ideal for drug development targeting myosin-2". Journal of Pharmacology and Experimental Therapeutics.
- ^ López-Dávila AJ, Chalovich JM, Zittrich S, Piep B, Matinmehr F, Málnási-Csizmadia A, et al. (2020-03-24). "Cycling Cross-Bridges Contribute to Thin Filament Activation in Human Slow-Twitch Fibers". Frontiers in Physiology. 11: 144. doi:10.3389/fphys.2020.00144. PMC 7105683. PMID 32265723.